Many people think of new medicines as bullets, and in the pharmaceutical industry, frequently used terms like “targets” and “hits” reinforce that idea. Immuneering co-founder and CEO Ben Zeskind ’03, Ph.D. ’06 prefers a different analogy. His company, which specializes in bioinformatics and computational biology, sees many effective drugs more like noise-canceling headphones. Rather than […]